# Bulk RNA sequencing dataset of Claudin-low breast cancer cell lines with Neuropilin-1 knockdown

## TL;DR

This paper provides a detailed RNA sequencing dataset of claudin-low breast cancer cells with Neuropilin-1 knockdown, offering insights into potential therapeutic targets.

## Contribution

The study introduces a novel comprehensive transcriptomic dataset of claudin-low breast cancer cell lines with NRP1 knockdown.

## Key findings

- Bulk RNA sequencing reveals the transcriptomic landscape of claudin-low breast cancer cell lines.
- NRP1-regulated signaling pathways are identified through RNA sequencing data.
- The dataset serves as a valuable resource for future therapeutic target studies.

## Abstract

Triple-negative breast cancers (TNBC) are a particularly aggressive breast cancer subtype with poor prognosis and high relapse rates. Due to a lack of identified targeted therapies, chemotherapy currently remains as the primary treatment for TNBC. Approximately 25–39% of TNBC are claudin-low breast cancers, which are mainly defined by low expression of cell-cell adhesion proteins and enrichment of mesenchymal signatures. Functional studies have demonstrated the potential role of the transmembrane-coreceptor, Neuropilin-1 (NRP1) in regulating the progression of these tumours. However, there have been no high-throughput studies to date that comprehensively investigate NRP1-modulated cell-signalling across multiple claudin-low cell lines. Therefore, we treated HS578T, MDA-MB-231 and SUM159PT claudin-low cell lines with either a non-targeting (NT) control or two NRP1-targeting small-interfering RNA (siRNA) or short-hairpin RNA (shRNA) sequences and followed this with bulk-RNA sequencing. We present this comprehensive transcriptomic dataset which provides a valuable resource for understanding both the transcriptomic landscape of claudin-low breast cancer and NRP1-regulated signalling pathways. Therefore, paving the way for future studies of its potential as a therapeutic target.